Drug Profile
CSL 346
Alternative Names: 2H10; CSL-346Latest Information Update: 17 Nov 2022
Price :
$50
*
At a glance
- Originator Zenyth Therapeutics
- Developer CSL; Zenyth Therapeutics
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action Fatty acid modulators; Vascular endothelial growth factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies
- No development reported Type 2 diabetes mellitus
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 24 Oct 2022 CSL Behring completes a phase IIa trial in Diabetic nephropathies in USA, Australia, Canada, Israel, New Zealand and Puerto Rico (IV, SC) (NCT04419467)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Diabetic-nephropathies in Australia (SC, Injection)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Australia (IV, Infusion)